Maintrac Customised Combination Testing
Maintrac’s Customised Combination test is used to identify, count, analyse and test existing escapee CTCs in a blood sample and is a comprehensive evaluation of a person’s CTCs. It includes a CTC Count, Companion Diagnostics (biomarker) testing and Customised Chemosensitivity. The test is customised specifically for each patient by the requesting doctor.
The best way to monitor cancer activity and long-term effectiveness of treatment is via a single CTC Count test every 3-6 months. Patient information hand-outs for your clinic are available upon request by phoning 1300 292 482.
Customised Combination Test - Patient Information
Publication: Epithelial cell dissemination and readhesion: Analysis of factors contributing to metastasis formation in breast cancer (2012) ...Read this publication
Publication: An increase in cell number at the completion of therapy may develop as an indicator of early relapse (2008) ...Read this publication
Publication: Monitoring Circulating Epithelial Tumour Cells (CETC) to gauge therapy: in patients with disease progression after tratsuzumab persisting CETC can be eliminated by combined lapatinib treatment (2008) ...Read this publication
Publication: Assessing the efficacy of targeted therapy using Circulating Epithelial Tumor Cells (CETCs): the example of SERM therapy monitoring as a unique tool to individualise therapy (2010) ...Read this publication
Publication: Chemosensitivity testing of Circulating Epithelial Tumour Cells (CETCs) in Vitro: Correlation to in Vivo sensitivity and clinical outcome ...Read this publication
Publication: Efficacy of control of therapy using Circulating Epithelial Tumor Cells (CETCs) as "Liquid Biopsy": trastuzumab in HER2/neu-positive breast carcinoma (2011) ...Read this publication
Publication: Insulin-like Growth Factor Receptor I (IGR-IR) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) are expressed on the Circulating Epithelial Tumor Cells of breast cancer patients ...Read this publication